Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Sell
27
CRBP Quote, Financials, Valuation and Earnings
Last price:
$13.14
Seasonality move
:
76.81%
Day range:
$12.70 - $13.32
52-week range:
$5.30 - $61.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
76.55x
P/B ratio:
1.07x
Volume:
135.5K
Avg. volume:
309.9K
1-year change:
139.45%
Market cap:
$160.4M
Revenue:
--
EPS (TTM):
-$4.67
Analysts' Opinion
-
Consensus RatingCorbus Pharmaceuticals Holdings has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $55.00, Corbus Pharmaceuticals Holdings has an estimated upside of 331.12% from its current price of $13.17.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $52.00 representing 100% downside risk from its current price of $13.17.
Fair Value
-
According to the consensus of 2 analysts, Corbus Pharmaceuticals Holdings has 331.12% upside to fair value with a price target of $55.00 per share.
CRBP vs. S&P 500
-
Over the past 5 trading days, Corbus Pharmaceuticals Holdings has underperformed the S&P 500 by -10.48% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Corbus Pharmaceuticals Holdings does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Corbus Pharmaceuticals Holdings revenues have been falling on a year-over-year basis for 7 quarters in a row. In the most recent quarter Corbus Pharmaceuticals Holdings reported revenues of --.
Earnings Growth
-
Corbus Pharmaceuticals Holdings has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Corbus Pharmaceuticals Holdings reported earnings per share of -$1.15.
Enterprise value:
1M
EV / Invested capital:
--
Price / LTM sales:
76.55x
EV / EBIT:
--
EV / Revenue:
0.68x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.03x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$34M | -$45.8M | -$46.2M | -$9.5M | -$15.5M | |
| EBITDA | -$33M | -$38.3M | -$43.2M | -$8.9M | -$13.3M | |
| Diluted EPS | -$9.95 | -$11.17 | -$4.67 | -$2.27 | -$1.15 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $85.4M | $111.7M | $67.3M | $31.2M | $160.9M | |
| Total Assets | $95.8M | $119.6M | $73.8M | $36.3M | $164.2M | |
| Current Liabilities | $41.4M | $17.1M | $17.5M | $31.5M | $11.6M | |
| Total Liabilities | $66.6M | $41.9M | $31.9M | $36M | $13.7M | |
| Total Equity | $29.2M | $77.6M | $41.9M | $311K | $150.5M | |
| Total Debt | $17.9M | $18.6M | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$39.8M | -$37.5M | -$36.9M | -$7.2M | -$13.9M | |
| Cash From Investing | $15.1M | $37M | -$119.7M | $10.9M | -$15.4M | |
| Cash From Financing | -- | -$681.7K | $164.7M | -$821K | $25M | |
| Free Cash Flow | -$39.8M | -$37.5M | -$36.9M | -$7.2M | -$13.9M | |
CRBP
Sector
Market Cap
$160.4M
$46.1M
Price % of 52-Week High
21.28%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
139.46%
-30.52%
Beta (5-Year)
2.575
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$13.70
200-day SMA
Sell
Level
$37.46
Bollinger Bands (100)
Sell
Level
12.18 - 48.02
Chaikin Money Flow
Sell
Level
-15M
20-day SMA
Sell
Level
$15.32
Relative Strength Index (RSI14)
Sell
Level
27.18
ADX Line
Sell
Level
25.65
Williams %R
Buy
Level
-86.1257
50-day SMA
Sell
Level
$16.65
MACD (12, 26)
Sell
Level
-1.33
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Neutral
Level
403M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Stock Forecast FAQ
In the current month, CRBP has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CRBP average analyst price target in the past 3 months is $55.00.
-
Where Will Corbus Pharmaceuticals Holdings Stock Be In 1 Year?
According to analysts, the consensus estimate is that Corbus Pharmaceuticals Holdings share price will rise to $55.00 per share over the next 12 months.
-
What Do Analysts Say About Corbus Pharmaceuticals Holdings?
Analysts are divided on their view about Corbus Pharmaceuticals Holdings share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Corbus Pharmaceuticals Holdings is a Sell and believe this share price will drop from its current level to $52.00.
-
What Is Corbus Pharmaceuticals Holdings's Price Target?
The price target for Corbus Pharmaceuticals Holdings over the next 1-year time period is forecast to be $55.00 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CRBP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Corbus Pharmaceuticals Holdings is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CRBP?
You can purchase shares of Corbus Pharmaceuticals Holdings via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Corbus Pharmaceuticals Holdings shares.
-
What Is The Corbus Pharmaceuticals Holdings Share Price Today?
Corbus Pharmaceuticals Holdings was last trading at $13.14 per share. This represents the most recent stock quote for Corbus Pharmaceuticals Holdings. Yesterday, Corbus Pharmaceuticals Holdings closed at $13.17 per share.
-
How To Buy Corbus Pharmaceuticals Holdings Stock Online?
In order to purchase Corbus Pharmaceuticals Holdings stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
60
QMCO alert for Dec 26
Quantum [QMCO] is up 49.62% over the past day.
Buy
53
ARQQ alert for Dec 26
Arqit Quantum [ARQQ] is up 49.85% over the past day.
Buy
65
TSLL alert for Dec 26
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 3.73% over the past day.
